The global hepatitis C virus (HCV) testing market size is expected to accumulate US$ 785.3 million in value by 2023 end. During the forecast period ranging from 2023 to 2033, a CAGR worth 5.4% has been projected for the market, with an expected closing value worth US$ 1,326.7 million. From 2018 to 2022, the industry unfolded at a value CAGR worth 4.6%.
The growing burden of infectious diseases on the global healthcare system is a significant consideration, with developing countries bearing a disproportionate share of the burden. Over time, the burden of hepatitis C virus infection has accelerated. According to the Institute of Liver and Biliary Sciences India, around 3% of the world's population is infected with the hepatitis C virus.
In 80 percent of infected patients, HCV did cause chronic infection. Initial hepatitis C virus testing employs serological assays to detect antibodies against HCV in blood samples. According to the Centers for Disease Control and Prevention (CDC) guidelines for hepatitis C screening, a cut-off ratio for anti-HPV antibodies is added, which aids in the selection of additional assays for confirmation of screening results.
The Nucleic Acid Amplification Test (NAT) is used to confirm and determine viral load. Regarding all constructive HCV antibody tests, an RNA test is performed. HCV genotyping tests are used in clinical HPV management to determine viral load and optimal treatment duration. Also, the use of non-sterile needles for tattooing and body piercing is a common cause of hepatitis C virus infection spread.
Attributes | Key Statistics |
---|---|
Global Market CAGR (2023 to 2033) | 5.4% |
Anticipated Market Value (2023) | US$ 785.3 million |
Global Market (2033) | US$ 1,326.7 million |
Global Market Attraction | The rising prevalence of hepatitis C virus infection fueled by inadequate blood donation strategies |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising prevalence of hepatitis C virus infection is the primary driver of the global hepatitis C virus testing market. Inadequate blood donation strategies are the leading cause of hepatitis C virus infection. Also, hepatitis C screening is required before organ donation, and growing organ donation projects around the world are expected to drive future growth.
The introduction of point-of-care opioid testing products for HCV testing raises the potential for HCV testing kits. The FDA approved the OraQuick HCV Rapid Antibody Test in 2010, and it is now widely used as an alternative to enzyme immunoassay testing for HCV. Also, the use of new electrochemical immuno-sensor and nano-sensor technologies in HPV testing is expected to change current practices.
Factors that are limiting the adoption of hepatitis C virus testing include:
Country/ Region | Market Share (2022) |
---|---|
North America | 33.4% |
The United States | 29.5% |
An estimated 12.5-40% of detained people in North America have HCV-antibody positivity, supporting the recommendation to screen this population for HCV infection and increasing market demand.
Infection with the Hepatitis C virus (HCV) is a leading cause of morbidity and mortality in the United States. HCV is primarily transmitted via parenteral exposure to infectious blood or body fluids containing blood, most commonly through injection drug use. With 8-12 weeks of all-oral medication regimens, direct-acting antiviral treatment can result in a virologic cure in most people. This factor is increasing market demand in North America.
HCV infection rates nearly doubled among women with live births in North America between 2009 and 2014, as new HCV infections increased among reproductive-aged adults. As a result, this factor is expected to drive market growth in this region. As per Future Market Insights, North America is likely to account for more than 33.4% of the global Hepatitis C virus testing market in 2023.
Attribute | Details |
---|---|
Europe’s Market Share (2022) | 30.7% |
Germany’s Market Share (2022) | 10% |
The United Kingdom’s Forecast CAGR (2023 to 2033) | 5.7% |
In 2023, Europe is forecasted to account for more than 30.7% share in the hepatitis C virus testing market, and is projected to maintain this growth throughout the forecast period, states Future Market Insights.
According to a research paper published in the medical journal BMJ Open in August 2020, HCV diagnosis rates in Germany are projected to exceed 70% by 2030 under the current approach. Such encouraging trends in HCV testing in the country are expected to significantly aid market growth during the forecast period.
In Europe, Hepatitis C is one of the most common infectious diseases. Several initiatives in the region have been inaugurated to better understand disease trends, such as prevalence and the most widely known genotypes. It is a liver disease caused by the hepatitis C virus (HCV), and it can contribute to the development of liver cancer if left untreated.
Germany has historically had a low prevalence of hepatitis C than developing countries. However, the country's demographics have changed in recent years. Also, the increasing influx of migrants and rising drug abuse through injections among the general population are projected to augment the country's hepatitis C prevalence.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The swelling dispersion of start-ups in the hepatitis C virus testing market has improved product quality and elevated global sales. Besides, to gain a competitive edge, new start-ups are working on novel developments and launching new products. Moreover, some notable players offering hepatitis C virus testing kits are as follows:
Start-up’s Name | Product in Detail |
---|---|
NATSpert | NATSpert, established in 2017 in Pune, India, is a developer of blood detection kits for viral diseases. Its product- NATSpert ID TripleH is a qualitative, real-time PCR test for the simultaneous detection of HIV, HBV, and HCV respectively. The kit comes in a single tube format and allows for screening of HIV type 1 group M-RNA, HIV-1 group-O RNA, HIV-2 RNA, Hepatitis C Virus RNA, and Hepatitis B Virus DNA in human blood plasma. |
HepC | Founded in 2005, HepC is a developer of antiviral biologic products. The company deploys IBDV, a non-pathogenic double-stranded RNA virus. This virus acts as a master activator of antiviral gene responses as its primary vector system. Its product development includes HC001 for treating advanced chronic viral hepatitis caused by HBV and HCV infections. |
Some of the manufacturers identified in the global hepatitis C virus testing market include OraSure Technologies, Inc., Abbott Laboratories Inc., Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Ortho Clinical Diagnostic Inc. (Johnson & Johnson), Bayer AG, QIAGEN N.V., Thermo Fisher Scientific Inc., BioGenex, AccuQuick, Roche Diagnostics (H. Hoffman-La Roche Ltd.), STD Rapid Test Kits, etc. among others.
Discover Recent Occurrences Shaping the Market
Organization’s Name | Roche |
---|---|
Nature of Development | Roche releases Novel Hepatitis C Virus Diagnostic test. |
Key Particulars About the Event | Roche has introduced a new dual antibody and antigen diagnostic testing called Elecys HCV Duo immunoassay to treat the hepatitis C virus. The test is launched in countries that permit the CE Mark. |
Organization’s Name | WHO and the University of BRISTOL |
---|---|
Nature of Development | WHO Collaborated with the University of BRISTOL to lead the research related to HCV. |
Key Particulars About the Event | A new study exhibits the advantages of a quick clinic-based diagnostic test for HCV infection over a general laboratory-based test. The discoveries from the study have resulted in the WHO recommending the adoption of the point-of-care (POC) HCV test. These rapid tests make HCV diagnosis close and accessible to the community. |
Organization’s Name | Mylab |
---|---|
Nature of Development | Pune’s Mylab Introduces Rapid Test Kits to rapidly Detect HCV, HIV, and Syphilis. |
Key Particulars About the Event | Mylab Discovery Solutions, a Pune-based company, announced in February 2023, that it is releasing three new rapid tests to quickly detect STIs. STIs pose a grave hurdle as WHO predicts that the caseload of STIs is going to reach 1 million/day, globally. |
Organization’s Name | J MITRA |
---|---|
Nature of Development | J MITRA releases 4th Gen Elisa-based HCV Test. |
Key Particulars About the Event | In September 2022, J Mitra, which is an IVD Company, introduced the HCV Gen 4 Ag & Ab Microlisa, which is a 4th generation Elisa-based HCV Test. The kit aims to screen blood donations to detect and discard infection units of blood. The kit is also used as a clinical diagnostic test for Hepatitis C. |
Organization’s Name | Access Bio Inc. and Atomo Diagnostics |
---|---|
Nature of Development | Access Bio Inc. and Atomo Diagnostics revealed the development of RDT. |
Key Particulars About the Event | Access Bio Inc. and Atomo Diagnostics announced the development of a rapid diagnostic test (RDT) for screening for the hepatitis C virus in April 2019. (HCV). The tests were commercially available by the end of this year 2019. |
Organization’s Name | Gilead Sciences Inc. |
---|---|
Nature of Development | Gilead Sciences Inc. reported the HepConnect Initiative. |
Key Particulars About the Event | Gilead Sciences Inc. announced the HepConnect initiative to reduce hepatitis C infections in Great Appalachia in March 2019. |
Report Attributes | Details |
---|---|
Growth Rate | CAGR of 5.4% from 2023 to 2033 |
Market Value in 2023 | US$ 785.3 million |
Market Value in 2033 | US$ 1,326.7 million |
Base Year for Estimation | 2022 |
Historical Period | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
This market is estimated to reach US$ 1,326.7 million by 2033.
North America expanded at a market share of 33.4% in 2022.
Limited access to regular healthcare restrains the market growth.
Infectious diseases drive sales, hitting global healthcare and developing nations.
North America holds a substantial share of the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technique
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Technique, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technique, 2023 to 2033
5.3.1. Immunoassays-based Hepatitis C Virus Testing
5.3.2. Polymerase Chain Reaction-based (PCR) Hepatitis C Virus Testing
5.3.3. Other Hepatitis C Virus Testing Techniques
5.4. Y-o-Y Growth Trend Analysis By Technique, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Technique, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033
6.3.1. HCV Antibody Testing
6.3.2. HCV Viral Load Testing
6.3.3. HCV Genotyping Testing
6.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033
7.3.1. Hepatitis C Virus Testing in Hospitals
7.3.2. Hepatitis C Virus Testing in Diagnostic Centers
7.3.3. Hepatitis C Virus Testing in Blood Donation Centers
7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Technique
9.2.3. By Test Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Technique
9.3.3. By Test Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Technique
10.2.3. By Test Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Technique
10.3.3. By Test Type
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Technique
11.2.3. By Test Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Technique
11.3.3. By Test Type
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Technique
12.2.3. By Test Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Technique
12.3.3. By Test Type
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Technique
13.2.3. By Test Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Technique
13.3.3. By Test Type
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Technique
14.2.3. By Test Type
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Technique
14.3.3. By Test Type
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Technique
15.2.3. By Test Type
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Technique
15.3.3. By Test Type
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Technique
16.1.2.2. By Test Type
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Technique
16.2.2.2. By Test Type
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Technique
16.3.2.2. By Test Type
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Technique
16.4.2.2. By Test Type
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Technique
16.5.2.2. By Test Type
16.5.2.3. By End User
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Technique
16.6.2.2. By Test Type
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Technique
16.7.2.2. By Test Type
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Technique
16.8.2.2. By Test Type
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Technique
16.9.2.2. By Test Type
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Technique
16.10.2.2. By Test Type
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Technique
16.11.2.2. By Test Type
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Technique
16.12.2.2. By Test Type
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Technique
16.13.2.2. By Test Type
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Technique
16.14.2.2. By Test Type
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Technique
16.15.2.2. By Test Type
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Technique
16.16.2.2. By Test Type
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Technique
16.17.2.2. By Test Type
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Technique
16.18.2.2. By Test Type
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Technique
16.19.2.2. By Test Type
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Technique
16.20.2.2. By Test Type
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Technique
16.21.2.2. By Test Type
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Technique
16.22.2.2. By Test Type
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Technique
16.23.2.2. By Test Type
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Technique
17.3.3. By Test Type
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. OraSure Technologies, Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Abbott Laboratories Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Siemens Healthcare GmbH
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Bio Rad Laboratories Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Ortho Clinical Diagnostic Inc. (Johnson & Johnson)
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Bayer AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. QIAGEN N.V.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Thermo Fisher Scientific Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. BioGenex
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. AccuQuick,
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Roche Diagnostics (F. Hoffman-La Roche Ltd.)
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. STD Rapid Test Kits
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports